AI & ChatGPT searches , social queriess for HER2
Search references for HER2. Phrases containing HER2
See searches and references containing HER2!
Search references for HER2. Phrases containing HER2
See searches and references containing HER2!HER2
Mammalian protein found in humans
family, HER2 does not directly bind ligand. HER2 activation results from heterodimerization with another ERBB member or by homodimerization when HER2 concentration
HER2
Cancer that originates in mammary glands
20% of tumors contain HER2; these can be treated with HER2-targeted therapies. The remainder that do not contain ER, PR, or HER2 are called "triple-negative"
Breast_cancer
Medication
epidermal growth factor receptor 2 (HER2/neu) on cancers that rely on it for growth. Additionally, once bound to HER2 receptors, the antibody is internalized
Trastuzumab_deruxtecan
Pharmaceutical drug
agent DM1. Trastuzumab alone stops growth of cancer cells by binding to the HER2 receptor, whereas trastuzumab emtansine undergoes receptor-mediated internalization
Trastuzumab_emtansine
Chemical compound
estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast
Vepdegestrant
Medication
breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor positive. It may be used by itself or together with other chemotherapy
Trastuzumab
Pharmaceutical drug
the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer. Side
Pertuzumab
Medication
treatment of HER2-positive biliary tract cancer. It is an IgG-like bispecific HER2-directed antibody directed against two non-overlapping domains of HER2. Zanidatamab
Zanidatamab
British breast cancer campaigner (1952 – 2009)
whose tumors have too much HER2 protein. This type of cancer is known as "HER2-positive", "HER2+", or "HER2 overexpressing". HER2+ tumors tend to grow and
Ann_Marie_Rogers
Pharmaceutical drug
treatment of various HER2-positive cancers. It comprises a humanized monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via
Disitamab_vedotin
Medication
Zongertinib is a kinase inhibitor of human epidermal growth factor receptor 2 (HER2). It is taken by mouth. Zongertinib was approved for medical use in the United
Zongertinib
Chemical compound
the Roche Group, for the treatment of estrogen receptor-positive (ER+), HER2-negative advanced breast cancer, as well as endometrial cancer, ovarian cancer
Giredestrant
Cancer medication
which interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathways. It is used in combination therapy for HER2-positive breast cancer
Lapatinib
Medication for HR+ HER2– breast cancer
is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the cyclin-dependent
Palbociclib
Medical classification system
basal-like or triple negative. HER2-low has some HER2 proteins on the cell surface, but not enough to be classified as HER2-positive. Trastuzumab deruxtecan
Breast_cancer_classification
Chemical compound
Imlunestrant is indicated for the treatment of adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease
Imlunestrant
Chemical compound
anticancer medication used for the treatment of HER2-positive breast cancer. It is a small molecule inhibitor of HER2. It was developed by Array BioPharma and
Tucatinib
Chemical compound
hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an
Inavolisib
Medication
or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations. The US prescribing information
Sevabertinib
Anti-breast cancer medication
hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after
Abemaciclib
Type of breast cancer lacking certain gene expressions
progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) overexpression and/or gene amplification (i.e. the tumor is negative on
Triple-negative_breast_cancer
Investigational drug
drug developed by Pfizer for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer. The drug is a first-in-class selective
Prifetrastat
Type of spreading cancer
epidermal growth factor receptor 2 (HER2) can be treated with HER2-targeted therapies. Tumors that do not contain ER, PR, or HER2 are called "triple-negative"
Metastatic_breast_cancer
Antibody-drug conjugate
breast cancer, previously treated metastatic hormone receptor–positive, HER2-negative breast cancer, and metastatic urothelial cancer. The most common
Sacituzumab_govitecan
Any type of epithelial lung cancer other than small-cell lung carcinoma
Trastuzumab deruxtecan, a HER2-directed ADC, received regulatory approval for previously treated metastatic NSCLC harboring activating HER2 (ERBB2) mutations
Non-small-cell_lung_cancer
Chemical compound
of adults with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting
Neratinib
Human breast cancer cell line
Center in 1970 that is used in therapeutic research, especially in context of HER2 targeting. SkBr3 cells were derived from a pleural effusion due to an adenocarcinoma
SKBR3
Chemical compound
hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase
Ribociclib
Combination drug
treat adults with HER2-positive breast cancer that has spread to other parts of the body, and for treatment of adults with early HER2-positive breast cancer
Pertuzumab/trastuzumab/hyaluronidase
Pertuzumab/trastuzumab/hyaluronidase
CDK4-specific inhibitor
treatment of various solid tumors, particularly hormone receptor-positive, HER2-negative breast cancer. The safety and efficacy of atirmociclib have not
Atirmociclib
American biotechnology corporation
HER2 gene. Recently approved for adjuvant therapy for breast cancer. FDA also recently approved Trastuzumab for metastatic gastric cancer with HER2 receptor
Genentech
Macromolecular complex containing protein and RNA molecules
induce cell-cycle arrest in response to DNA damage by ionizing radiation. HER2 is overexpressed in 20-30% of breast cancers and is commonly associated with
Heterogeneous ribonucleoprotein particle
Heterogeneous_ribonucleoprotein_particle
Any chemical that inhibits the function of CDKs
postmenopausal women with breast cancer that is estrogen receptor positive and HER2 negative. While there are multiple cyclin/CDK complexes regulating the cell
CDK_inhibitor
Cancerous tumor originating in the stomach lining
over-expressing the HER2/neu gene. In particular, HER2 is overexpressed in 13–22% of patients with gastric cancer. Of note, HER2 overexpression in gastric
Stomach_cancer
American biologist
overexpression of HER2 a significant driver in tumor progression and how does this work? Shepard and Hudziak discovered that too much HER2 made tumor cells
H._Michael_Shepard
Class of biopharmaceutical drugs
and Roche) was approved in February 2013 for the treatment of people with HER2-positive metastatic breast cancer (mBC) who had received prior treatment
Antibody–drug_conjugate
Chemical compound
approved for use in combination with fulvestrant for treatment of HR-positive, HER2-negative recurrent, or metastatic breast cancer in patients who have progressed
Dalpiciclib
Signaling within the same cell
In HER2 overexpressing breast cancers, the HER2–IL-6–STAT3 signaling relationship could be targeted to develop new therapeutic strategies. HER2 kinase
Autocrine_signaling
Hospital in Singapore
given wrong test results for the human epidermal growth factor receptor 2 (HER2) test to 180 breast cancer patients and 90 breast cancer patients may have
Khoo_Teck_Puat_Hospital
Medication
datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer". U.S. Food and Drug Administration (FDA). 17 January
Datopotamab_deruxtecan
Chemical compound
the treatment of androgen receptor-positive, estrogen receptor-negative, HER2-negative advanced breast cancer. Vosilasarm was also previously under development
Vosilasarm
Monoclonal antibody
name Margenza, is a chimeric IgG monoclonal antibody medication against HER2 used for the treatment of cancer. The most common adverse drug reactions
Margetuximab
Drug typically used in cancer treatment
closely related protein tyrosine kinases such as EGFR and its close relative HER2. Numerous TKIs aiming at various tyrosine kinases have been generated by
Tyrosine_kinase_inhibitor
Chemical compound
that also irreversibly inhibits human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases. Afatinib is not only
Afatinib
South Korean biopharmaceutical company
early and advanced (metastatic) HER2+ breast cancer as well as advanced (metastatic) stomach cancer. Herzuma is a HER2+ breast cancer therapy designed
Celltrion
Upward spreading of abnormal cells in the epidermis
confirmed through biopsy, often using immunohistochemical markers such as CK7, HER2, and GCDFP-15 to distinguish Paget’s cells. Treatment options include: Surgical
Pagetoid
Proteins engineered to bind to target proteins or peptides
selectively to HER2 receptors with picomolar affinity. These Affibody molecules are in clinical development for tumor diagnosis. Anti-HER2 Affibody molecule
Affibody_molecule
Hormonal antineoplastic drug
in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with abemaciclib or palbociclib
Fulvestrant
associated with a particular disease. HER2 is an established therapeutic target within breast cancer, and the activation of HER2 is observed in approximately 20%
Cancer_pharmacogenomics
Topics referred to by the same term
(IATA code HER) Khoy, Armenia (historical name) Hydrogen evolution reaction HER2/neu, a protein Hercules (constellation) Hydroxyethylrutoside, a flavonoid
Her
Test for early stage breast cancer
of TargetPrint ER, PR and Her2 results with Oncotype DX ER, PR and Her2 and with locally assessed IHC/FISH ER, PR and Her2 Compare clinical subtype based
MammaPrint
Chemical compound
study, copanlisib was effective in inhibiting HER2+ breast cancer cells with acquired resistance to the HER2-inhibitors trastuzumab and/or lapatinib. This
Copanlisib
Pharmaceutical compound
trial in 708 participants with locally advanced or metastatic HR-positive, HER2-negative breast cancer, of which 289 participants had tumors with
Capivasertib
Monoclonal antibody
advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma whose tumors
Zolbetuximab
Chemical compound
phase I study (NCT03471663) evaluated taragarestrant in females with ER+/HER2- advanced or metastatic breast cancer, both as monotherapy and in combination
Taragarestrant
Therapeutic drug diagnostic test
immunohistochemistry staining machine for microscopy slides to highlight HER2 expression. This machine is classified by the U.S. Food and Drug Administration
Companion_diagnostic
Chemical compound
estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated, advanced or metastatic breast cancer with disease
Elacestrant
Indian multinational pharmaceutical company
In September 2025 licensed Hengrui’s trastuzumab rezetecan (SHR‑A1811), a HER2‑targeted ADC, for selected markets, with milestone‑linked economics disclosed
Glenmark_Pharmaceuticals
Pharmaceutical drug used in cancer treatment
first-line treatment of people with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. Approval
Pembrolizumab
Chemical compound
United States and June 2019, in the European Union for germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer. In January 2024, the
Talazoparib
Vaccine that either treats existing cancer or prevents development of cancer
immune system and enhance antigenicity. Examples of these epitopes include Her2 peptides, such as GP2 and NeuVax. However, this approach requires MHC profiling
Cancer_vaccine
but suffering from HER2+ breast cancer receives AVEC, consisting of the antibody against HER2 and vaccine against HBV (AVEC: anti-HER2 - HBV). Since this
Antibody-vaccine engineered construct
Antibody-vaccine_engineered_construct
(ER and/or PR positive; HER2 negative) Luminal B (ER and/or PR positive; HER2 positive) HER2-enriched (ER/PR negative; HER2 positive) Basal like (triple
Endocrine therapy resistance in breast cancer
Endocrine_therapy_resistance_in_breast_cancer
American oncologist
research considers new diagnostic strategies and treatment pathways for HER2 positive breast cancer. Lin was trained in medicine at Harvard Medical School
Nancy_Lin
Chemical compound
Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2- Metastatic Breast Cancer". International Journal of Breast Cancer. 2020
Gedatolisib
Medication
cancer. It is a low-fucose humanized full-length immunoglobulin G1 bispecific HER2- and HER3-directed antibody. The most common adverse reactions include diarrhea
Zenocutuzumab
Class of enzymes
approved for HR+/HER2- advanced breast cancer. Abemaciclib may be used in monotherapy, in addition to combination treatment, for certain HR+/HER2- breast cancer
Cyclin-dependent_kinase
Chemical compound
Buparlisib was under investigation as a treatment for advanced or metastatic HER2-negative breast cancer in several phase III clinical trials: The phase III
Buparlisib
unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer,
List of drugs granted breakthrough therapy designation
List_of_drugs_granted_breakthrough_therapy_designation
Type of cytotoxic lymphocyte
NK-92 variant that expresses a CAR for HER2 (ErbB2) has been generated and is in a clinical study in patients with HER2 positive glioblastoma. Several other
Natural_killer_cell
Canadian biotechnology company
monotherapy can provide durable disease control in patients with a variety of HER2-expressing solid tumors that have progressed following standard of care treatments
Zymeworks
Chemical compound
follow-up study of a Phase 2 randomized controlled trial in early-stage, HER2-negative breast cancer demonstrated that mechanical conditioning of cancer
Nintedanib
2008 American TV series or program
student assistant Jennifer Coolidge as Tish, participant in Phase One of the Her2 study Angie Harmon as Lilly Tartikoff, wife of Brandon Tartikoff (NBC Television
Living_Proof_(2008_film)
Medical condition
oncogenes like HER2/neu. Histologic factors associated with worse prognosis include high histologic grade, hormone receptor negativity, and HER2 negativity
Invasive carcinoma of no special type
Invasive_carcinoma_of_no_special_type
Pharmaceutical compound
Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab Pertuzumab Trastuzumab Trastuzumab
E2511
Spanish oncologist (1959–2021)
breast cancer treatment Herceptin, a monoclonal antibody, that targets the HER2 protein, which is impacted in aggressive breast cancers. He served as Physician-in-Chief
José_Baselga
Monoclonal antibody
conjugated to antibodies targeting at human epidermal growth factor receptor 2(HER2) has been developed. Mechanically, immune stimulating antibody conjugates
Immune stimulating antibody conjugate
Immune_stimulating_antibody_conjugate
Protein-coding gene in the species Homo sapiens
been shown to be overexpressed in conjunction with HER2 in breast cancer cases. Murine models of HER2 overexpression in conjunction with PTPN1 knockout
PTPN1
Chemotherapy combined with immunotherapy
cancer overexpressing HER2, chemoimmunotherapy also shows better results. The HER2 gene, which encodes the growth factor receptor HER2, is overexpressed in
Chemoimmunotherapy
2011 Canadian TV series or program
Narrated by Kim Cattrall, the film profiles a number of women battling the HER2 strain of breast cancer. A shorter version of the film premiered at Toronto's
About_Her
Classification of secretion of exocrine glands
patient cannot express the estrogen receptor, progesterone receptor, or HER2 receptor. "Apocrine | Meaning of Apocrine by Lexico". Lexico Dictionaries
Apocrine
French oncologist
Institute. He is best known for his research on treatments with trastuzumab in HER2-positive breast cancers. Pivot was born on April 20, 1967, in Draguignan
Xavier_Pivot
Medical condition
individuals with HER2/neu-positive PACB tumors and ~72% for individuals with HER2/neu-negative PACB tumors. Since 9 of the 17 HER2/neu-positive individuals
Pure apocrine carcinoma of the breast
Pure_apocrine_carcinoma_of_the_breast
Protein-coding gene in the species Homo sapiens
therapeutically resistant HER2+ xenograft models. Inhibition of HER2 and CDK7 resulted in tumor regression in therapeutically resistant HER2+ xenograft models
Cyclin-dependent_kinase_7
Family of four EGF proteins
bind to and activate the erbB family of receptor tyrosine kinases (erbB2 (HER2), erbB3 (HER3), and erbB4 (HER4)), functioning both as heterodimers and homodimers
Neuregulin
Australian comedian
Bonnie Lane. Scott was diagnosed with an aggressive form of breast cancer (HER2-positive) just before embarking on the Mother and Son reboot, and underwent
Denise_Scott
Protein domain
portions of transmembrane proteins. For example, ADAM10 can cut off part of the HER2 receptor, thereby activating it. ADAM genes are found in animals, choanoflagellates
ADAM_(protein)
Class of enzymes
capable of binding to the extracellular domain of RTKs, has been used to treat HER2 overexpression in breast cancer. + Table adapted from "Cell signalling by
Receptor_tyrosine_kinase
Class of pharmaceutical drugs
alectinib+cobimetinib. Results for the last two are expected around 2020-2021. The EGFR and HER2 pathways are commonly abnormally activated in a large proportion of cancers
ALK_inhibitor
Medication
("-mab") Receptor tyrosine kinase ErbB: HER1/EGFR (Cetuximab Panitumumab) HER2/neu (Pertuzumab Trastuzumab (+hyaluronidase) Trastuzumab emtansine Trastuzumab
Elranatamab
Common application of immunostaining
extracellular receptor domain regulating an intracellular tyrosine kinase. Of these, HER2/neu (also known as Erb-B2) was the first to be developed. The molecule is
Immunohistochemistry
Medical condition
individualized therapies: in particular, the EGF receptor family (EGFR and HER2), KIT, and androgen receptors are the most commonly investigated molecular
Salivary_gland_tumour
Monoclonal antibody
alongside platinum- and fluoropyrimidine-based chemotherapy to treat people with HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal
Tislelizumab
Medical model that tailors medical practices to the individual patient
PMID 21964534. S2CID 205738875. Carney W (2006). "HER2/neu Status is an Important Biomarker in Guiding Personalized HER2/neu Therapy" (PDF). Connection. 9: 25–27
Personalized_medicine
Gene found in humans
HOTAIR-mediated overexpression of the HER2 oncogene through sequestration of miR-331-3p, which is a negative regulator of HER2 expression. In cells, especially
HOTAIR
American cancer researcher
therapies for those with brain metastases, including triple negative and HER2-positive breast cancer. Anders is a Fellow of the American Society of Clinical
Carey_K._Anders
Microscope that uses visible light
P; Hildenbrand, G; Hausmann, M; Cremer, C; et al. (2011). "Analysis of Her2/neu membrane protein clusters in different types of breast cancer cells using
Optical_microscope
Short RNA molecule
demonstrated miR-489 target HER2 and LAPTM4b by directly binding to their 3'UTR. Role of miR-489 has been studied in autochatothus MMTV-Her2 mouse model. MicroRNA
Mir-489 microRNA precursor family
Mir-489_microRNA_precursor_family
Biotechnology company
(eribulin) in participants with human epidermal growth factor receptor 2 (HER2)-negative, HA-high metastatic breast cancer (MBC). "Halozyme Therapeutics
Halozyme
Fragment
designed to reduce side effects of cardiac surgery C6.5, a diabody targeting HER2/neu found in some breast cancers Brolucizumab, a scFV binding to VEGF-A and
Single-chain variable fragment
Single-chain_variable_fragment
HER2
HER2
HER2
HER2
Boy/Male
Tamil
Male
Dutch
, high, lofty.
Boy/Male
Tamil
The Moon
Boy/Male
Indian
Another name of God, Evidence, Guide
Boy/Male
Hindu
Girl/Female
Hindu, Indian
Responsible
Girl/Female
Arabic, Muslim
Olive
Male
Arthurian
, the invisible knight.
Boy/Male
Tamil
Abundance, Powerful, Extensive
Girl/Female
Tamil
Likitha | லிகித , லீகீதா , லீகீதாÂ
Writing
HER2
HER2
HER2
HER2
HER2